botensilimab,balstilimab
agenus
agenus shows unprecedented activity for botensilimab/balstilimab combination in microsatellite stable colorectal cancer at esmo world gi congress - response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4... 
CEO Of Digital Media Online